Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles

Wrinkle Clinical Trial

Official title:

Clinical Evaluation of Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04057768
• Other study ID #: VI0919
• Status: Completed
• Phase: N/A
• Start date: August 19, 2019
• Est. completion date: March 3, 2020

Study information

• Verified date: June 2021
• Source: Venus Concept
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this clinical study is to evaluate the efficacy of fractional RF for the treatment and reduction of acne scarring or facial wrinkles.

Description:

Prospective, single centre, evaluator-blind, split face study of the efficacy of fractional radiofrequency (RF) for the treatment and reduction of acne scarring and facial wrinkles. The study will evaluate the progress of 15 subjects requesting treatment of scarring or facial wrinkles. The study will involve three treatments on both sides of the face with 3-5 week intervals between each treatment. Subjects will be followed at 6 and 12 weeks after their last treatment. Analysis will be performed on all subjects who receive at least one treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: March 3, 2020
• Est. primary completion date: March 3, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 22 Years and older

Eligibility

Inclusion Criteria:

1. Healthy, male or female subjects over 21 years of age who are seeking treatment and reduction of their acne scarring or wrinkles.

2. Able to read, understand and voluntarily provide written Informed Consent.

3. Able and willing to comply with the treatment/follow-up schedule and requirements.

4. Women of child-bearing age are required to be using a reliable method of birth control at least 3 months prior to study enrollment and for the duration of the study and have a negative Urine Pregnancy test at baseline.

Exclusion Criteria:

1. Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body (e.g. cochlear implant).

2. Subjects with any implantable metal device in the treatment area

3. Permanent implant in the treated area, such as metal plates and screws (excluding dental implants), or an injected chemical substance.

4. Current or history of any kind of cancer, or dysplastic nevi

5. Severe concurrent conditions, such as cardiac disorders.

6. Pregnancy or intending to become pregnant during the study and nursing.

7. Impaired immune system due to immunosuppressive diseases, such as AIDS and HIV, or use of immunosuppressive medications.

8. History of diseases stimulated by heat, such as recurrent herpes simplex in the treatment area; may be enrolled only following a prophylactic regime.

9. Poorly controlled endocrine disorders, such as diabetes.

10. Any active condition in the treatment area, such as sores, psoriasis, eczema, and rash.

11. History of skin disorders, such as keloids, abnormal wound healing, as well as very dry and fragile skin.

12. History of bleeding coagulopathies, or use of anticoagulants (excluding daily aspirin).

13. Facial dermabrasion, facial resurfacing, or deep chemical peeling within the last three months, if face is treated.

14. Use of isotretinoin (Accutane®) or other systemic retinoids within six months prior to treatment or as per investigators discretion.

15. Any surgical procedure in the treatment area within the last six months or before complete healing.

16. Treating over tattoo or permanent makeup.

17. Excessively tanned skin from sun, tanning beds or tanning creams within the last two weeks.

Related Conditions & MeSH terms

• Acne Scars - Mixed Atrophic and Hypertrophic
• Acne Vulgaris
• Hypertrophy
• Wrinkle

Intervention

Device:
• Venus Viva
The Venus Viva™ fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids and scars.

Locations

Country	Name	City	State
United States	Laser and Skin Surgery Center of Northern California	Sacramento	California

Sponsors (1)

Lead Sponsor	Collaborator
Venus Concept

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Wrinkle Improvement Assessed by the Fitzpatrick Wrinkle and Elastosis Scale (FWES) at 12 Weeks Post-Final Treatment	Evaluate the efficacy of overall facial wrinkles improvement assessed live by the Investigator and a subject assessment of facial appearance including the Fitzpatrick Wrinkle and Elastosis Scale (FWES).; The FWES is a 9 point scale.; Three independent evaluators evaluated before and after photographs and graded them for change.; Possible responses were: a score of 1 - 3 (Mild) indicates fine texture changes with subtly accentuated skin lines, a score of 4 - 6 (Moderate) indicates distinct papular elastosis ([indvidual papules with yellow translucency under direct lighting] and dyschromia and a score of 7 - 9 (Severe) indicates multipapular and confluent elastosis [thickened yellow and pallid] approaching or consistent with cutis rhomboidalis. A lower class and a lower score means a better outcome.	12 Weeks Post-Final Treatment
Primary	Overall Acne Scar Improvement Assessed by the Global Aesthetic Improvement Scale (GAIS) at 12 Weeks Post-Final Treatment	Evaluate the efficacy of overall facial acne scar improvement assessed live by the Investigator and a subject assessment of facial appearance including the Global Aesthetic Improvement Scale (GAIS).; The Global Aesthetic Improvement Scale is a seven-grade subjective test.; Three independent evaluators evaluated before and after photographs and graded them for change.; Possible responses were (3) Very Much Improved, (2) Much Improved, (1) Improved, (0) No Change, (-1) Worse, (-2) Much Worse, and (-3) Very Much Worse. For reporting of outcomes, the higher the GAIS value, the greater the improvement (Range -3 to 3).	12 Weeks Post-Final Treatment
Secondary	Subject Satisfaction	Subjects' assessment of satisfaction with the treatment using a 5 point Subject Satisfaction Scale at 6 Weeks and 12 weeks post-treatment.; The Subject Satisfaction Scale is a five-grade subjective test.; Participant were asked their satisfaction level post treatment.; Possible responses were (4) Very Satisfied, (3) Satisfied, (2) Having No Opinion, (1) Unsatisfied, and (0) Very Unsatisfied.	6 and 12 Weeks Post- Final Treatment
Secondary	Subject Scale - Wong Baker FACES Pain Scale	Subject's assessment of discomfort and pain after treatments as measured by a 10 point Wong-Baker FACES Pain Scale; The Wong-Baker FACES pain scoring system is a subject-reported instrument using a scale of 0 (no pain) to 10 (most pain).; Possible responses, 9 to 10 shows Hurts Worst, 7 to 8 shows Hurts Whole Lot, 5 to 6 shows Hurts Even More, 3 to 4 shows Hurts Little More, 1 to 2 shows Hurts Little Bit, 0 shows No Hurt.	12 Weeks Post-Final Treatment
Secondary	Subject Scale - 5 Point Scale for Treatment Tolerability	Subject's assessment of treatment tolerability as measured by a 5 point scale.; Participant were asked their tolerability level post treatment.; Possible scores were; (4) Very Tolerable, (3) Tolerable, (2) Having No Opinion, (1) Intolerable, and (0) Very Intolerable.	8 Weeks Post-Final Treatment
Secondary	Number of Participants With Treatment-Related Adverse Events	Subjects experiencing a treatment-related adverse event (AE) by 12 weeks post-treatment.; A treatment-related adverse event was any untoward medical occurrence attributed to the device in a participant who received treatment. Relatedness to the device was assessed by the investigator.	Up to 12 Weeks Post-Treatment